ATP6V1G1
Aliases:
This biomarker is also known as:- ATP6G1
- ATP6V1G1
- vacuolar proton pump subunit G 1
- ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J
- vacuolar H(+)-ATPase subunit G 1
- ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1
- V-ATPase 13 kDa subunit 1
- Vacuolar proton pump subunit M16
- ATP6J
- ATP6G
- Vacuolar proton pump subunit G 1
- ATP6GL
- Vma10
- vacuolar proton pump subunit M16
- DKFZp547P234
- vacuolar ATP synthase subunit M16
- V-ATPase subunit G 1
- V-type proton ATPase subunit G 1
- ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G isoform 1
Description…
ATP6V1G1 is a subunit of vacuolar ATPase (V-ATPase), a multisubunit enzyme. V-ATPase is an enzyme transporter that functions to acidify intracellular compartments in eukaryotic cells. This acidification process is necessary for such intracellular processes as protein sorting, zymogen activation, receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase is ubiquitously expressed and is present in endomembrane organelles such as vacuoles, lysosomes, endosomes, the Golgi apparatus, chromaffin granules and coated vesicles, as well as in the plasma membrane. V-ATPase is composed of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of three A, three B, and two G subunits, as well as a C, D, E, F, and H subunit. The V1 domain contains the ATP catalytic site.
Datasets
There are no datasets associated with this biomarker.
Attributes
QA State: | Curated |
---|---|
Type: | Protein |
HGNC Name: | ATP6V1G1 |
The following organs have data associated with this biomarker…
Attributes
Phase: | 2 |
---|---|
QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Multianalyte tests for the early detection of cancer: speedbumps and barriers.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.